{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:45:03Z","timestamp":1781196303493,"version":"3.54.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.autrev.2019.102409","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T12:43:19Z","timestamp":1571661799000},"page":"102409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cannabinoids in the treatment of rheumatic diseases: Pros and cons"],"prefix":"10.1016","volume":"18","author":[{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Ablin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adva","family":"Trabelsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ann","family":"Fitzcharles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Marotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"H\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2019.102409_bb0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S1516-44462006000200015","article-title":"History of cannabis as a medicine: a review","volume":"28","author":"Zuardi","year":"2006","journal-title":"Braz J Psychiatry"},{"issue":"2","key":"10.1016\/j.autrev.2019.102409_bb0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.mayocp.2011.10.003","article-title":"Blurred boundaries: the therapeutics and politics of medical marijuana","volume":"87","author":"Bostwick","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.autrev.2019.102409_bb0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF02862859","article-title":"An archaeological and historical account of cannabis in China","volume":"28","author":"Li","year":"1974","journal-title":"Econ Bot"},{"issue":"1","key":"10.1016\/j.autrev.2019.102409_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02791072.1981.10471447","article-title":"The religious and medicinal uses of Cannabis in China, India and Tibet","volume":"13","author":"Touwn","year":"1981","journal-title":"J Psychoactive Drugs"},{"issue":"6","key":"10.1016\/j.autrev.2019.102409_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw1391","article-title":"The origins of cannabis smoking: chemical residue evidence from the first millennium BCE in the Pamirs","volume":"5","author":"Ren","year":"2019","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/j.autrev.2019.102409_bb0030","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd.2018.115","article-title":"New approaches and challenges to targeting the endocannabinoid system","volume":"17","author":"Di Marzo","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.autrev.2019.102409_bb0035","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bmc.2015.01.059","article-title":"Cannabidiol (CBD) and its analogs: a review of their effects on inflammation","volume":"23","author":"Burstein","year":"2015","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.autrev.2019.102409_bb0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","article-title":"Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis","volume":"45","author":"Blake","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2019.102409_bb0045","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar2401","article-title":"Characterization of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis","volume":"10","author":"Richardson","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2019.102409_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12950-016-0114-7","article-title":"The synthetic cannabinoid WIN55, 212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB 2, TRPV1, TRPA1 and yet unidentified receptor targets","volume":"13","author":"Lowin","year":"2016","journal-title":"J Inflamm (Lond)"},{"issue":"17","key":"10.1016\/j.autrev.2019.102409_bb0055","doi-asserted-by":"crossref","first-page":"9561","DOI":"10.1073\/pnas.160105897","article-title":"The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis","volume":"97","author":"Malfait","year":"2000","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.autrev.2019.102409_bb0060","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.imbio.2014.12.012","article-title":"Activation of cannabinoid receptor 2 attenuates synovitis and joint destruction in collagen-induced arthritis","volume":"220","author":"Gui","year":"2015","journal-title":"Immunobiology."},{"key":"10.1016\/j.autrev.2019.102409_bb0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/1471-2474-15-275","article-title":"Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis","volume":"15","author":"Fukuda","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"10.1016\/j.autrev.2019.102409_bb0070","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/art.20050","article-title":"A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis","volume":"50","author":"Sumariwalla","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2019.102409_bb0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0091-3057(97)00583-2","article-title":"Characterization of \u03949-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats","volume":"60","author":"Smith","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.autrev.2019.102409_bb0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.intimp.2015.03.006","article-title":"The endocannabinoid system and its therapeutic implications in rheumatoid arthritis","volume":"26","author":"Gui","year":"2015","journal-title":"Int Immunopharmacol"},{"issue":"113","key":"10.1016\/j.autrev.2019.102409_bb0085","first-page":"3","article-title":"One year in review 2018: systemic sclerosis","volume":"36","author":"Orlandi","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2019.102409_bb0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.autrev.2019.102409_bb0095","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/art.27642","article-title":"Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis","volume":"62","author":"Marquart","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2019.102409_bb0100","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.24395","article-title":"The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2019.102409_bb0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2018-eular.3512","article-title":"OP0006 Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial jbt101-ssc-001","volume":"77","author":"Spiera","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102409_bb0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2017-eular.2712","article-title":"OP0126 A phase 2 study of safety and efficacy of anabasum (JBT-101) in systemic sclerosis","volume":"76","author":"Spiera","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102409_bb0115","author":"ClinicalTrials.gov [Internet]. Bethesda (MD)"},{"issue":"11","key":"10.1016\/j.autrev.2019.102409_bb0120","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.jid.2017.05.035","article-title":"Cannabinoid reduces inflammatory cytokines, tumor necrosis factor-\u03b1, and type I interferons in dermatomyositis in vitro","volume":"137","author":"Robinson","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2019.102409_bb0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/annrheumdis-2018-eular.3531","article-title":"FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis","volume":"77","author":"Werth","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2019.102409_bb0130","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/annrheumdis-2018-eular.5629","article-title":"SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001","volume":"77","author":"Werth","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102409_bb0135","author":"ClinicalTrials.gov [Internet]. Bethesda (MD)"},{"issue":"1","key":"10.1016\/j.autrev.2019.102409_bb0140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.berh.2014.01.004","article-title":"The epidemiology of osteoarthritis","volume":"28","author":"Johnson","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2019.102409_bb0145","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/j.1532-2149.2014.499.x","article-title":"Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review","volume":"18","author":"Lluch","year":"2014","journal-title":"Eur J Pain"},{"issue":"107","key":"10.1016\/j.autrev.2019.102409_bb0150","first-page":"68","article-title":"Pain sensitization in osteoarthritis","volume":"35","author":"Arendt-Nielsen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2019.102409_bb0155","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.joca.2015.04.020","article-title":"The type 2 cannabinoid receptor regulates susceptibility to osteoarthritis in mice","volume":"23","author":"Sophocleous","year":"2015","journal-title":"Osteoarthr Cartil"},{"issue":"11","key":"10.1016\/j.autrev.2019.102409_bb0160","doi-asserted-by":"crossref","first-page":"e80440","DOI":"10.1371\/journal.pone.0080440","article-title":"Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint","volume":"8","author":"Burston","year":"2013","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.autrev.2019.102409_bb0165","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.2014.3266","article-title":"Fibromyalgia: a clinical review","volume":"311","author":"Clauw","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.autrev.2019.102409_bb0170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/j.pain.0000000000001390","article-title":"The IASP classification of chronic pain for ICD-11: chronic primary pain","volume":"160","author":"Nicholas","year":"2019","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.autrev.2019.102409_bb0175","first-page":"192","article-title":"Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?","volume":"29","author":"Russo","year":"2008","journal-title":"Neuro Endocrinol Lett"},{"issue":"2","key":"10.1016\/j.autrev.2019.102409_bb0180","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","article-title":"Nabilone for the treatment of pain in fibromyalgia","volume":"9","author":"Skrabek","year":"2008","journal-title":"J Pain"},{"key":"10.1016\/j.autrev.2019.102409_bb0185","series-title":"Ottawa (ON): Canadian Agency for Drugs and Technologies in Health","article-title":"Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness and Guidelines \u2013 An Update","author":"McGolrick","year":"2018"},{"key":"10.1016\/j.autrev.2019.102409_bb0190","series-title":"The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research","article-title":"Engineering, and medicine","author":"National Academies of Sciences","year":"2017"},{"issue":"7","key":"10.1016\/j.autrev.2019.102409_bb0195","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/art.40451","article-title":"Neurobiologic features of fibromyalgia are also present among rheumatoid arthritis patients","volume":"70","author":"Basu","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2019.102409_bb0200","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/art.40152","article-title":"Changing trends in opioid use among patients with rheumatoid arthritis in the United States","volume":"69","author":"Curtis","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"14","key":"10.1016\/j.autrev.2019.102409_bb0205","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jama.2015.12397","article-title":"Addressing the opioid epidemic","volume":"314","author":"Nelson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2019.102409_bb0210","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1001\/jama.2015.6407","article-title":"Medical marijuana: is the cart before the horse?","volume":"313","author":"D'Souza","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.autrev.2019.102409_bb0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.autrev.2019.102409_bb0220","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ejp.1118","article-title":"Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - an overview of systematic reviews","volume":"22","author":"H\u00e4user","year":"2018","journal-title":"Eur J Pain"},{"issue":"6","key":"10.1016\/j.autrev.2019.102409_bb0225","doi-asserted-by":"crossref","first-page":"755","DOI":"10.36076\/ppj.20.5.E755","article-title":"A systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Aviram","year":"2017","journal-title":"Pain Physician"},{"issue":"1","key":"10.1016\/j.autrev.2019.102409_bb0230","first-page":"79","article-title":"The perils of overestimating the efficacy of Cannabis-based medicines for chronic pain management","volume":"21","author":"H\u00e4user","year":"2017","journal-title":"Pain Physician"},{"key":"10.1016\/j.autrev.2019.102409_bb0235","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies","volume":"59","author":"Stockings","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.autrev.2019.102409_bb0240","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2019.102409_bb0245","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jpain.2015.07.009","article-title":"Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data","volume":"16","author":"Andreae","year":"2015","journal-title":"J Pain"},{"issue":"3","key":"10.1016\/j.autrev.2019.102409_bb0250","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/phar.1709","article-title":"Nabilone for the Management of Pain","volume":"36","author":"Tsang","year":"2016","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.autrev.2019.102409_bb0255","first-page":"CD011694","article-title":"Cannabinoids for fibromyalgia","volume":"7","author":"Walitt","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.102409_bb0260","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","article-title":"The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial","volume":"110","author":"Ware","year":"2010","journal-title":"Anesth Analg"},{"issue":"6","key":"10.1016\/j.autrev.2019.102409_bb0265","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/rheumatology\/kel114","article-title":"The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by\u202frheumatoid arthritis","volume":"45","author":"Wright","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.102409_bb0270","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00508-006-0611-4","article-title":"Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain \u2013 a randomized controlled trial","volume":"118","author":"Pinsger","year":"2006","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.autrev.2019.102409_bb0275","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2019.102409_bb0280","first-page":"627","article-title":"Cannabinoids in pain management and palliative medicine","volume":"114","author":"H\u00e4user","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.autrev.2019.102409_bb0285","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.autrev.2019.102409_bb0290","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","article-title":"An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia","volume":"160","author":"Van de Donk","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.autrev.2019.102409_bb0295","author":"Government of Canada"},{"key":"10.1016\/j.autrev.2019.102409_bb0300","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.autrev.2019.102409_bb0305","first-page":"346","article-title":"Balancing benefits and harms","author":"Godlee","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2019.102409_bb0310","first-page":"CD012182","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.102409_bb0315","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1097\/j.pain.0000000000000706","article-title":"Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis","volume":"157","author":"Ste-Marie","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.autrev.2019.102409_bb0320","article-title":"Long-term opioid therapy of non-cancer pain: Prevalence and predictors of hospitalization in the event of possible misuse","author":"H\u00e4user","year":"2018","journal-title":"Schmerz"},{"key":"10.1016\/j.autrev.2019.102409_bb0325","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/ADM.0000000000000405","article-title":"Medical marijuana users are more likely to use prescription drugs medically and nonmedically","volume":"12","author":"Caputi","year":"2018","journal-title":"J Addict Med"},{"key":"10.1016\/j.autrev.2019.102409_bb0330","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/ejp.1297","article-title":"European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management","volume":"22","author":"H\u00e4user","year":"2018","journal-title":"Eur J Pain"},{"key":"10.1016\/j.autrev.2019.102409_bb0335","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3899\/jrheum.181120","article-title":"Position statement: a pragmatic approach for medical cannabis and patients with rheumatic diseases","volume":"46","author":"Fitzcharles","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2019.102409_bb0340","first-page":"111","article-title":"Simplified guideline for prescribing medical cannabinoids in primary care","volume":"64","author":"Allan","year":"2018","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.autrev.2019.102409_bb0345","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41584-018-0025-5","article-title":"Cannabinoids for the treatment of rheumatic diseases \u2013 where do we stand?","volume":"14","author":"Katz-Talmor","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2019.102409_bb0350","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ejp.1185","article-title":"Medical cannabis: a forward vision for the clinician","volume":"22","author":"Fitzcharles","year":"2018","journal-title":"Eur J Pain"},{"key":"10.1016\/j.autrev.2019.102409_bb0355","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1097\/j.pain.0000000000001295","article-title":"Systematic reviews with meta-analysis on cannabis-based medicines for chronic pain: a methodological and political minefield","volume":"59","author":"H\u00e4user","year":"2018","journal-title":"Pain"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:16:05Z","timestamp":1761599765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219302162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":71,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1568997219302162"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102409","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids in the treatment of rheumatic diseases: Pros and cons","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102409"}}